CEO Michael Cohen to become Executive Chairman; COO James Lovett to be promoted to CEO
Norristown, PA, April 2, 2019 — Myoderm, a global clinical trial supply company, today announced that effective July 1, 2019, Michael Cohen, currently Chief Executive Officer, will transition to Executive Chairman of the company and James Lovett, the current Chief Operating Officer, will assume the role of Chief Executive Officer and will report to Michael. In addition, Myoderm’s President Robby Cohen will also take on the role of Co-Chairman.
The moves are the result of the company’s growth in recent years. Under Michael’s leadership, Myoderm has expanded service offerings and strengthened manufacturer and sourcing partnerships around the globe, in addition to opening a second facility in the UK and expanding the employee base. With Lovett assuming overall leadership as CEO, Michael will focus on strategic growth opportunities.
Since being named COO in 2017, Lovett has been key in identifying new ways to serve clients in the evolving industry and improving internal operations to benefit employees and clients. Before joining Myoderm, he served as a Senior Vice President of Princeton, NJ-based Covance Inc., a global contract research organization and drug development services company, where he led three different business units with consistent success, as well as served as General Counsel. A trustee of the Wistar Institute, an international leader in biomedical research, he previously played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.
“James’ broad experience prepares him well to lead Myoderm to the next stage of growth and beyond,” said Michael Cohen. “Over the last two years, I’ve gotten to know him well and appreciate his many talents. Together, we will take our company to new heights and contribute meaningfully to medical advances by providing the much-needed supplies for broad-based and global clinical trials.”
“This is an amazing time to be at Myoderm,” added Lovett. “With the strong foundation that Michael has built, and our growth potential in the marketplace, I am very proud and excited to assist Michael and Robby in taking the company to the next level.”